# Systemic Inflammatory Disease

This is a subcategory of Immunomodulator Agents.

## Formulary

### Preferred

| Preferred     | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Enbrel PA     |              |          |             |
| Humira PA     |              |          |             |
| Kineret PA    |              |          |             |
| Otezla PA     |              |          |             |
| Taltz PA ST   |              |          |             |
| Xeljanz IR PA |              |          |             |

### Non-Preferred

| Non-Preferred   | Generic Name | Quantity | Time (Days) |
| :-------------- | :----------- | :------: | :---------: |
| Actemra         |              |          |             |
| Adbry           |              |          |             |
| Cibinqo         |              |          |             |
| Cimzia          |              |          |             |
| Cosentyx        |              |          |             |
| Dupixent        |              |          |             |
| Ilumya          |              |          |             |
| Kevzara         |              |          |             |
| Olumiant        |              |          |             |
| Orencia         |              |          |             |
| Rinvoq          |              |          |             |
| Siliq           |              |          |             |
| Simponi         |              |          |             |
| Skyrizi         |              |          |             |
| Stelara         |              |          |             |
| Tremfya         |              |          |             |
| Xeljanz Sol, XR |              |          |             |

## Length of Authorizations

Initial: 90 days; Subsequent: 365 days

**All Authorizations**

Must be prescribed in accordance with FDA approved labeling

## Additional Criteria

### Clinical PA

-   Must have been an inadequate clinical response of at least **90 days** with at least **two applicable** first-line drugs indicated for diagnosis – provide documentation of the trialed drugs, dosages, dates, and durations
-   Authorization of dosing regimens (loading/maintenance) will be based upon diagnosis. Document the requested loading and maintenance dosing on PA form, if applicable
-   Must not have a current, active infection
-   Must provide evidence of negative TB test prior to initiation of biologic therapy, if required by labeling

### Step Therapy

Step Therapy Approval Criteria

-   Must have had an inadequate clinical response of at least **90 days** with at least **one preferred** TNF inhibitor indicated for diagnosis.

### Non-Preferred

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **90 days** with at least **two preferred** drugs, if indicated for diagnosis
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Atopic Dermatitis

Additional Atopic Dermatitis Criteria

-   Must be prescribed by or in consultation with a dermatologist or allergist/immunologist
-   Must have at least 10% body surface area (BSA) involvement with **two** of the following: topical corticosteroids, topical calcineurin inhibitors [e.g. Elidel], or topical PDE-4 inhibitors [e.g. Eucrisa] OR atopic dermatitis severe and involves \>25% BSA

### Plaque Psoriasis

Additional Plaque Psoriasis Criteria

-   For patients currently receiving phototherapy, an inadequate clinical response of at least **90 days** must be shown prior to initial authorization for preferred drugs

### Ulcerative Colitis

Additional Ulcerative Colitis Criteria

-   If an inadequate clinical response after **90 days** with one TNF inhibitor, further TNF inhibitors will not be authorized

### Subsequent Authorization

-   Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=71)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=25)
